Search research articles
Contact Us
Filters
Showing results (161-170 of 293) with videos related to
Page
of 30
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 29, 2018
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
Cody J Peer, Oliver M Hall, Tristan M Sissung, et al.
Molecular and Cellular Biochemistry
|
November 13, 2008
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant
Orsolya Polgar, John F Deeken, Lilangi S Ediriwickrema, et al.
Oncogene
|
January 16, 2002
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
Philippe C Bishop, Timothy Myers, Robert Robey, et al.
Cancer Research
|
April 5, 2012
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter
Agnes Basseville, Akina Tamaki, Caterina Ierano, et al.
Cell Cycle (Georgetown, Tex.)
|
April 23, 2005
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin
April R Robbins, Sandra A Jablonski, Tim J Yen, et al.
Molecular Pharmacology
|
November 7, 2007
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan
Zhiyong Liao, Robert W Robey, Josée Guirouilh-Barbat, et al.
Cancer Research
|
November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors
Jerry Jaboin, Jason Wild, Habib Hamidi, et al.
Molecular Cancer Therapeutics
|
December 17, 2002
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity
Mikhail V Blagosklonny, Robert Robey, Dan L Sackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2012
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth
Wilfred D Stein, Julia Wilkerson, Sindy T Kim, et al.
Cancer Biology & Therapy
|
February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li, George Cusatis, Julie Brahmer, et al.
Page
of 30
Search research articles
Search
Showing results (161-170 of 293) with videos related to
Sort By:
Page
of 30
Cancer Chemotherapy and Pharmacology
|
June 29, 2018
A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat
Cody J Peer, Oliver M Hall, Tristan M Sissung, et al.
Molecular and Cellular Biochemistry
|
November 13, 2008
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant
Orsolya Polgar, John F Deeken, Lilangi S Ediriwickrema, et al.
Oncogene
|
January 16, 2002
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
Philippe C Bishop, Timothy Myers, Robert Robey, et al.
Cancer Research
|
April 5, 2012
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter
Agnes Basseville, Akina Tamaki, Caterina Ierano, et al.
Cell Cycle (Georgetown, Tex.)
|
April 23, 2005
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin
April R Robbins, Sandra A Jablonski, Tim J Yen, et al.
Molecular Pharmacology
|
November 7, 2007
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan
Zhiyong Liao, Robert W Robey, Josée Guirouilh-Barbat, et al.
Cancer Research
|
November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors
Jerry Jaboin, Jason Wild, Habib Hamidi, et al.
Molecular Cancer Therapeutics
|
December 17, 2002
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity
Mikhail V Blagosklonny, Robert Robey, Dan L Sackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2012
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth
Wilfred D Stein, Julia Wilkerson, Sindy T Kim, et al.
Cancer Biology & Therapy
|
February 22, 2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
Jing Li, George Cusatis, Julie Brahmer, et al.
Page
of 30